Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Peritonitis

PHASE4CompletedINTERVENTIONAL
Enrollment

180

Participants

Timeline

Start Date

January 10, 2018

Primary Completion Date

December 3, 2019

Study Completion Date

December 3, 2019

Conditions
PeritonitisIntoxication
Interventions
DRUG

Rheosorbilact®

Administered intravenously (with speed 40-60 drip per minute) at a dose of 600 to 1,000 ml (10 to 15 ml/kg body weight per 24 hours) for 3 days.

DRUG

Ringer lactate

Administered intravenously (with speed 40-60 drip per minute) at a dose of 1,000 to 2,500 ml (15 to 40 ml/kg body weight per 24 hours) for 3 days.

Trial Locations (10)

Unknown

"Unimedi Adjara LLC", Batumi

Kutaisi Referral Hospital, Kutaisi

JSC EVEX/LTD Traumatology, Tbilisi

Institute of Ambulance, Chisinau

Municipal Clinical Hospital, Chisinau

Republican Clinical Hospital, Chisinau

Institute of General and Urgent Surgery of the National Academy of Medical Sciences of Ukraine, Kharkiv

Kyiv City Clinical Hospital No.4; National Medical University named after O.O. Bogomolets, Kyiv

"HSEE of Ukraine Ukrainian Medical Stomatological Academy; Poltava Central District Hospital", Poltava

Republic Centre of Ambulance, Tashkent

All Listed Sponsors
lead

Yuria-Pharm

INDUSTRY

NCT03771170 - Efficacy and Safety of Rheosorbilact® Solution for Infusion, in a Complex Therapy of Peritonitis | Biotech Hunter | Biotech Hunter